News - PsychoGenics

News | Publications | Posters | Upcoming Events |

2020 | 2019 | 2018 | 2017 | 2016 | 2015 and Earlier |

September 25, 2020
PsychoGenics Further Strengthens its Leadership Team, Adding Three Senior Executives
September 16, 2020
PsychoGenics Drug Discovery Featured in Nature Biopharma Dealmakers
July 28, 2020
Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration
November 6, 2019
PsychoGenics Awarded NIH HEAL Initiative Contract for Preclinical Screening Platform for Pain (PSPP)
November 4, 2019
PsychoGenics Appoints Mark A. Varney, PhD as Chief Scientific Officer
October 30, 2019
PsychoGenics Announces Milestones Associated with Sunovion’s Advancing Pipeline
September 27, 2019
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia
May 10, 2019
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
December 13, 2018
Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia
March 15, 2018
PsychoGenics Obtains License to the TgF344-AD Rat Model of Alzheimer’s Disease
December 4, 2017
Blue Oak & PsychoGenics Announce a Drug Discovery Partnership
June 12, 2017
PsychoGenics Achieves a Milestone in Drug Discovery Collaboration with Sunovion
April 4, 2016
PsychoGenics Drug Discovery Collaboration with Sunovion Achieves a Milestone
January 27, 2016
PsychoGenics Obtains a License to the Line – 41 Mouse Model of Alzheimer’s Disease
January 19, 2016
PsychoGenics Expands its Drug Discovery Service Capabilities
January 12, 2016
PsychoGenics and the Alzheimer’s Drug Discovery Foundation Announce a Risk-Sharing Partnership for Preclinical Studies
September 14, 2015
PsychoGenics Extends its Drug Discovery Collaboration with Sunovion
August 11, 2015
PsychoGenics Obtains a License to Another Transgenic Mouse Model of α-Synucleinopathies
March 15, 2015
PsychoGenics Obtains a License to α-synuclein Transgenic Mouse Models of Parkinson´s disease
March 2, 2015
Resilience and PsychoGenics Announce a Drug Discovery Partnership
January 27, 2015
PsychoGenics Achieves Another Milestone in Drug Discovery Collaboration with Sunovion
January 21, 2015
PsychoGenics Obtains a License to the McGill-R-Thy1-APP Rat Model of Alzheimer’s Disease
June 9, 2014
PsychoGenics Receives License to the Cntnap2 Knockout Mouse Model from the Weizmann Institute
May 12, 2014
PsychoGenics Achieves Another Milestone in its Drug Discovery Collaboration with Sunovion
April 22, 2014
PsychoGenics and Roche Expand Their Drug Discovery Partnership
January 31, 2014
PsychoGenics Obtains a Non-Exclusive License to the rTg4510 Tauopathy Mouse Model
August 21, 2013
PsychoGenics Obtains an Exclusive License to the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease
June 17, 2013
PsychoGenics and Sunovion Pharmaceuticals Inc. Expand their Drug Discovery Partnership
November 5, 2012
PsychoGenics Achieves Substantial Milestone in its Drug Discovery Collaboration with Sunovion
July 16, 2012
Afraxis and PsychoGenics Form Alliance to Offer Afraxis’ ESP Technology for Drug Discovery
June 12, 2012
PsychoGenics Inc. Announces Positive Efficacy Data in Levodopa Induced Dyskinesia in Parkinson’s Patients.
February 8, 2012
PsychoGenics Expands its In Vivo Capabilities with the Addition of Preclinical Magnetic Resonance Imaging Technology Services in Partnership with Ekam Imaging.
November 16, 2011
PsychoGenics Achieves Milestone in its Discovery Collaboration with Roche
May 25, 2011
PsychoGenics and Evotec Enter into a Strategic Alliance to Provide Integrated CNS Drug Discovery Solutions
February 14, 2011
PsychoGenics Expands its In Vivo Testing Capabilities with the Addition of Novel Neurogenesis Techniques in Partnership with KineMed Inc.
February 18, 2010
PsychoGenics Inc. today announced the establishment of an exclusive alliance with Dr. Jan Kehr.
August 30, 2009
PsychoGenics and AstraZeneca Enter Agreement to Identify New Treatments for Central Nervous System Disorders
August 10, 2009
PsychoGenics Appoints David A. Lowe, as Chief Scientific Officer and Executive Vice President of Research and Development
August 25, 2008
PsychoGenics Appoints John McCall, Ph.D. as Newest Member to its Scientific Advisory Board (SAB)
June 2, 2008
PsychoGenics Announces Positive Phase-IIa for its First-in-Class Partial 5-HT1A – 5-HT1B Receptor Agonist in ADHD
May 28, 2008
PsychoGenics Appoints Bavani Shankar, as Vice President, Corporate Development
May 27, 2008
PsychoGenics and Roche Enter Agreement to Identify New Treatments for Neuropsychiatric Disorders
March 4, 2008
PsychoGenics and Dainippon Sumitomo Pharma Sign Drug Discovery Agreement
January 31, 2008
PsychoGenics Expands Drug Discovery Relationship With Eli Lilly and Company
November 7, 2007
PsychoGenics Announces Drug Discovery Agreement with Cephalon
April 13, 2007
Translational Research Forum to Explore Philanthropy and Drug Development At 2007 BIO International Convention.
January 30, 2007
PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals
January 1, 2007
PsychoGenics, together with the Ewing Marion Kauffman Foundation, sponsors the Translational Research Forum at the BIO 2007 International Convention.
December 19, 2006
PsychoGenics Announces Drug Discovery and Development Agreement with Eli Lilly and Company; Companies Will Work Together to Identify New Treatments for Neuropsychiatric Disorders
October 4, 2006
PsychoGenics Appoints Rusiko Bourtchouladze, Ph.D. as Vice President, Cognition and Discovery Research
September 22, 2006
PsychoGenics Expands Huntington Disease Research Collaboration with High Q Foundation and CHDI
April 10, 2006
PsychoGenics and Sosei Partner to Identify New CNS Therapies
February 24, 2006
PsychoGenics and SMA Foundation Extend Research Agreement
July 6, 2005
PsychoGenics to provide testing services in the R6/2 Mouse Model for Huntington Disease
November 15, 2004
PsychoGenics Names Paul McGonigle Chief Scientific Officer, and Jeff Schneider Chief Informatics Officer
August 28, 2002
PsychoGenics Obtains Funding For Their High Throughput CNS Drug Discovery Platform
June 11, 2002
Mark Hofer Esq. Joins PsychoGenics as General Counsel

CONTACT

PsychoGenics Inc.
215 College Road, Paramus, NJ 07652

Email: info@psychogenics.com

Phone: (914) 406-8019

Fax: (914) 406-8090

CONTACT

PsychoGenics Inc.
215 College Road, Paramus, NJ 07652

Email: info@psychogenics.com

Phone: (914) 406-8019

Fax: (914) 406-8090